Targeting neuraminidase—the 'N' in H1N1—could help prevent the flu and limit severity

April 5, 2018, University of Chicago Medical Center
Blue tetramers are the neuraminidase glycoprotein and the brown trimers are the hemagglutinin glycoprotein. Neuraminidase has long stood in the shadow of hemagglutinin, the major target of current influenza vaccine platforms. Neuraminidase should be included as a vaccine target. Credit: The Wilson lab, University of Chicago Medicine

Vaccines designed to protect people from the influenza virus tend to concentrate on hemagglutinin, one of the two prominently displayed proteins on the surface of the virus and the primary target for influenza prevention.

In the April 5, 2018, issue of the journal Cell, however, teams led by Patrick Wilson at the University of Chicago Medicine and Florian Krammer at the Icahn School of Medicine at Mt. Sinai Hospital in New York City argue that placing greater emphasis on the comparatively neglected protein, , could substantially decrease infection rates and reduce disease severity for those infected with the .

These two viral-surface glycoproteins have distinct roles. Hemagglutinin enables the virus to attach to a host's cell membranes and enter that person's . Once inside the cell, the virus makes multiple copies of itself. These copies then prepare to burst out of their hijacked cell and infect more cells.

The virus cannot get out of the cell, however, without help from the other protein. Neuraminidase facilitates egress. It enables newly formed to escape the original cell and infect nearby cells, where they multiply again, repeating the process and allowing the infection to spread rapidly throughout the body.

The Wilson and Krammer laboratories found that maintaining the structure of neuraminidase during the production of future influenza vaccines could substantially improve protection from influenza infection. Credit: Wikimedia Commons: PDB_1ivd_EBI

"Hemagglutinin activity has been the primary measure of influenza- efficacy for decades," said Wilson, the study's senior author and a professor of medicine at the University of Chicago. The current anti-flu vaccines concentrate on hemagglutinin. "But they do a poor job of stimulating the immune system to neutralize neuraminidase," Wilson said. "Neuraminidase, one of two prime targets, has been profoundly neglected. This leaves a big hole in immunity."

Interim estimates from the Centers for Disease Control and Prevention confirm the need for a more trustworthy vaccine. The U.S. Influenza Vaccine Effectiveness survey found that the vaccine's ability to protect people from influenza A or B during the period from November 2, 2017, to February 3, 2018, was a dismal 36 percent. That fell to 25 percent for the influenza A (H3N2) virus. In the previous three influenza seasons, effectiveness ranged from a low of 19 percent to a high of 48 percent.

So Wilson and colleagues focused instead on the neglected link. Neuraminidase is "highly immunogenic," he said. Infection induces nearly equal numbers of neuraminidase and hemagglutinin-reactive B cells. These cells produce the crucial antibodies that block activity of flu-related viral proteins.

But the current vaccines rarely trigger an effective response from neuraminidase-reactive B cells. "The hemagglutinin tends to maintain its structure," Wilson said, "but the neuraminidase, a more complicated, delicate four-part structure, breaks down. It sort of falls apart."

Patrick Wilson, who led the UChicago Medicine team, and study co-author Nai-Ying Zheng in a laboratory in the Knapp Center for Lupus and Immunology Research at the University of Chicago. Credit: The University of Chicago Medicine

As a result, the antibodies that should neutralize neuraminidase, locking potentially virulent viral particles inside infected cells, are much less effective. In many cases, the neuraminidase component of the vaccines triggers antibody production at levels "nearly 90-fold lower," the authors note, than antibodies aimed at hemagglutinin.

"The current vaccines rely on sub-units, small pieces of the neuraminidase protein, rather than the full target," Wilson said. "The current process of inactivating the vaccine seems to destroy the neuraminidase protein."

When the researchers tested monoclonal antibodies collected from unvaccinated mice that were infected with influenza, they found that those antibodies could provide robust protection. Even when given to mice 48 hours after infection with the virus, the neuraminidase-reactive antibodies were effective at levels comparable to the hemagglutinin-reactive , protecting the mice from a lethal influenza challenge.

"Our results demonstrate that hemagglutinin should no longer be the de-facto target in influenza vaccine development efforts," Wilson said. "We think including an improved neuraminidase component to future compositions can reduce the severity of illness and decrease the frequency of community-acquired influenza infections."

"With a robust response to neuraminidase," the authors conclude, "the degree of protection conferred might protect from any infection." It could even provide "broad-ranging protection," they suggest, "against potential pandemic strains that express N1 or N2 neuraminidases."

Explore further: Researchers discover a new way that influenza can infect cells

More information: "Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies," Cell (2018). DOI: 10.1016/j.cell.2018.03.030

Related Stories

Researchers discover a new way that influenza can infect cells

September 23, 2013
Scientists at Fred Hutchinson Cancer Research Center have uncovered a new mechanism by which influenza can infect cells – a finding that ultimately may have implications for immunity against the flu.

Flu infection study increases understanding of natural immunity

January 23, 2018
People with higher levels of antibodies against the stem portion of the influenza virus hemagglutinin (HA) protein have less viral shedding when they get the flu, but do not have fewer or less severe signs of illness, according ...

Lactic acid bacteria can protect against Influenza A virus, study finds

December 13, 2017
Lactic acid bacteria, commonly used as probiotics to improve digestive health, can offer protection against different subtypes of influenza A virus, resulting in reduced weight loss after virus infection and lower amounts ...

Nano-decoy lures human influenza A virus to its doom

October 25, 2016
To infect its victims, influenza A heads for the lungs, where it latches onto sialic acid on the surface of cells. So researchers created the perfect decoy: A carefully constructed spherical nanoparticle coated in sialic ...

Recommended for you

Researchers identify blood biomarkers that may help diagnose, confirm concussions

April 20, 2018
Researchers from the University of California, Irvine, Georgetown University and the University of Rochester have found that specific small molecules in blood plasma may be useful in determining whether someone has sustained ...

DOR protein deficiency favors the development of obesity

April 20, 2018
Obesity is a world health problem. Excessive accumulation of fat tissue (adipose tissue) increases the risk of cardiovascular disease, hypertension, diabetes and some types of cancer. However, some obese individuals are less ...

Stem-cell technology aids 3-D printed cartilage repair

April 20, 2018
Novel stem-cell technology developed at Swinburne will be used to grow the massive number of stem cells required for a new hand-held 3-D printer that will enable surgeons to create patient-specific bone and cartilage.

Enduring cold temperatures alters fat cell epigenetics

April 19, 2018
A new study in fat cells has revealed a molecular mechanism that controls how lifestyle choices and the external environment affect gene expression. This mechanism includes potential targets for next-generation drug discovery ...

Defect in debilitating neurodegenerative disease reversed in mouse nerves

April 19, 2018
Scientists have developed a new drug compound that shows promise as a future treatment for Charcot-Marie-Tooth disease, an inherited, often painful neurodegenerative condition that affects nerves in the hands, arms, feet ...

Molecule that dilates blood vessels hints at new way to treat heart disease

April 19, 2018
Americans die of heart or cardiovascular disease at an alarming rate. In fact, heart attacks, strokes and related diseases will kill an estimated 610,000 Americans this year alone. Some medications help, but to better tackle ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.